Canaccord analyst Whitney Ijem raised the firm's price target on Taysha Gene Therapies to $17 from $14 and keeps a Buy rating on the shares. The firm said the company reiterated dosing completion in both REVEAL and ASPIRE trials are expected in 2Q26. The FDA recently cleared initiation of ASPIRE, where n=3 pts, aged 2 to less than4yo will receive a 1E15 dose, but scaled down to account for the lower brain volume in the younger population. Up next, the firm is looking forward to the updated Part A data expected in 2Q26 where all N=12 pts will have a minimum of 12month follow-up, continued evidence of milestone gains and a clean safety profile will bode well for the pivotal.
